Targeted treatment of esophagogastric cancer
Adenocarcinoma of the esophagogastric junction (EGJ) and stomach remains one of the most common causes of cancer-related death worldwide. Although there is increasing data on the mutational landscape of esophagogastric cancer, phase III trials often yield negative results, and there is a paucity of...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
November 22, 2016
|
| In: |
Oncology research and treatment
Year: 2016, Jahrgang: 39, Heft: 12, Pages: 788-794 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000452877 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1159/000452877 Verlag, Volltext: https://www-karger-com.ezproxy.medma.uni-heidelberg.de/Article/FullText/452877 
|
| Verfasserangaben: | Hans-Georg Kopp, Ralf-Dieter Hofheinz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1587376725 | ||
| 003 | DE-627 | ||
| 005 | 20220815101058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190207s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000452877 |2 doi | |
| 035 | |a (DE-627)1587376725 | ||
| 035 | |a (DE-576)517376725 | ||
| 035 | |a (DE-599)BSZ517376725 | ||
| 035 | |a (OCoLC)1341035173 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kopp, Hans-Georg |d 1971- |e VerfasserIn |0 (DE-588)121889297 |0 (DE-627)081600828 |0 (DE-576)182119173 |4 aut | |
| 245 | 1 | 0 | |a Targeted treatment of esophagogastric cancer |c Hans-Georg Kopp, Ralf-Dieter Hofheinz |
| 264 | 1 | |c November 22, 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.02.2019 | ||
| 520 | |a Adenocarcinoma of the esophagogastric junction (EGJ) and stomach remains one of the most common causes of cancer-related death worldwide. Although there is increasing data on the mutational landscape of esophagogastric cancer, phase III trials often yield negative results, and there is a paucity of approved targeted agents. For the time being, the subset of patients carrying HER2-positive metastatic tumors can receive trastuzumab in addition to chemotherapy. Furthermore, ramucirumab has been found to be active both as a single agent and in combination with paclitaxel. Herein, we give an overview of currently approved targeted treatments for locally advanced/resectable as well as unresectable/metastatic EGJ/gastric adenocarcinoma, summarizing the underlying clinical studies. Moreover, further potential targets still under investigation are presented. | ||
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology research and treatment |d Basel : Karger, 2014 |g 39(2016), 12, Seite 788-794 |h Online-Ressource |w (DE-627)776629611 |w (DE-600)2749752-5 |w (DE-576)400081660 |x 2296-5262 |7 nnas |a Targeted treatment of esophagogastric cancer |
| 773 | 1 | 8 | |g volume:39 |g year:2016 |g number:12 |g pages:788-794 |g extent:7 |a Targeted treatment of esophagogastric cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000452877 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www-karger-com.ezproxy.medma.uni-heidelberg.de/Article/FullText/452877 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190207 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 65500 |e 60000PH121917517 |e 65500PH121917517 |k 0/60000/ |k 1/60000/65500/ |p 2 |y j | ||
| 999 | |a KXP-PPN1587376725 |e 3055280555 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1587376725","origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"November 22, 2016"}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"2014","publisher":"Karger","dateIssuedDisp":"2014-","publisherPlace":"Basel"}],"recId":"776629611","note":["Gesehen am 15.12.2023"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2749752-5"],"issn":["2296-5262"],"eki":["776629611"]},"disp":"Targeted treatment of esophagogastric cancerOncology research and treatment","language":["eng"],"part":{"text":"39(2016), 12, Seite 788-794","year":"2016","volume":"39","issue":"12","pages":"788-794","extent":"7"},"title":[{"title":"Oncology research and treatment","title_sort":"Oncology research and treatment"}],"pubHistory":["37.2014 -"]}],"note":["Gesehen am 07.02.2019"],"physDesc":[{"extent":"7 S."}],"id":{"eki":["1587376725"],"doi":["10.1159/000452877"]},"name":{"displayForm":["Hans-Georg Kopp, Ralf-Dieter Hofheinz"]},"person":[{"family":"Kopp","display":"Kopp, Hans-Georg","given":"Hans-Georg","role":"aut"},{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut"}],"language":["eng"],"title":[{"title_sort":"Targeted treatment of esophagogastric cancer","title":"Targeted treatment of esophagogastric cancer"}]} | ||
| SRT | |a KOPPHANSGETARGETEDTR2220 | ||